Miltefos 50 50 mg
Miltefosine
Category: Capsule
Manufacturer: Popular Pharmaceuticals Ltd.
Price: 165.0 ৳
30 in Blister Pack
Medicine Selling service is not available yet.
Related Medicines
Uses of Miltefos 50:
- Kala-azar
Visceral leishmaniasis, Mycosis fungoides, Skin metastases of breast cancer
Pregnancy, lactation, concurrent radiation therapy.
How to use
Miltefosine:
Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it.
Miltefosine is to be taken with food.
Adult Dose:
Adult : PO Visceral Leishmaniasis 100-150 mg/day for 28 days.
Child Dose:
Child: PO 2.5 mg/kg/day bid
>12 y: 30–44 kg: 100 mg/day bid
>45 kg: 150 mg/day tid
Miltefosine did not inhibit human cytochrome P450 enzymes in vitro.
Miltefosine did not induce cytochrome 3A activity in rats.
Pregnancy, lactation, concurrent radiation therapy.
Common
- Headache
- Nausea
- Itching
- Sleepiness
- Decreased appetite
- Abdominal pain
- Diarrhea
- Vomiting
- Dizziness
- Increased creatinine level in blood
- Increased liver enzymes
>10%
Visceral leishmaniasis
Increased transaminases, <3 x ULN (94%),Decreased platelets <150,000 (62%),Vomiting (37.8%),Decreased appetite (23.1%),Diarrhea (20.4%)
1-10%
Visceral leishmaniasis
Increased serum creatinine, >1.5 x baseline (10%),Asthenia (6.3%),Increased transaminases, 3-5 x ULN (6%),Decreased platelets <50,000 (2.4%)
Precaution:
Metastases grown over breast implants. Increased serum creatinine, ALT, AST, bilirubin reported; monitor. Thrombocytopenia reported; monitor platelets
Stevens-Johnson syndrome reported; discontinue if an exfoliative or bullous rash occurs
Lactation: Unknown if distributed in human breast milk; avoid breastfeeding during therapy and for 5 months following therapy
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Leishmaniacides
Miltefosine is a phospholipid derivative thought to work by disrupting cell-membrane function.
Pregnancy: Miltefosine should not be used during pregnancy. Obtain a urine or serum pregnancy test in females of reproductive potential prior to prescribing.Nursing Mothers: Discontinue drug or nursing depending on the importance of drug to the mother. Avoid breastfeeding for 5 months after Miltefosine therapy.Females and Males of Reproductive Potential: Advise females to use effective contraception during therapy and for 5 months after therapy. Advise patients of reproductive toxicities in animals, and that the potential for impaired fertility in humans has not been adequately evaluated
Samm Care